Intelligence / TB-500

TB-500

Prescription Only
Tissue Repair
Schedule
S4
Prescription Only
Enforcement
Monitoring
Medium Risk
Providers
8
Access: Limited
Key Facts
Schedule 4 - Prescription Only
Synthetic Thymosin Beta-4 fragment
8 identified Australian providers
Some pharmacies have discontinued
Grey market availability remains high

Overview

TB-500 is a synthetic version of a naturally occurring 43-amino acid peptide (Thymosin Beta-4). Prescription availability is more limited than BPC-157, with some compounding pharmacies discontinuing it. Grey market supply remains readily available.

Australian Scheduling

Schedule 4 (Prescription Only). Currently under monitoring by the TGA. Some compounding pharmacies have discontinued TB-500, potentially signalling increased regulatory caution.

Access Pathway

Available through select telehealth providers and compounding pharmacies, but with fewer options than other tissue repair peptides. 8 identified providers. The limited prescription supply has driven demand toward the grey market.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Curr Pain Headache Rep24 Aug 2026
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
Mol Biomed17 Aug 2026
Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway
Clin Sci (Lond)12 Aug 2026
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers
Associated Press23 July 2026
The Peptide Bodybuilders and Gym Bros Are Secretly Using to Recover Faster After Exercise
Men's Health20 July 2026
[Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study in vitro]
Zhongguo Dang Dai Er Ke Za Zhi15 July 2026
Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology.
Experimental eye research10 July 2026
Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome.
Frontiers in immunology22 June 2026
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
Investigative ophthalmology & visual science12 June 2026
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction trial posted on ClinicalTrials.gov
ClinicalTrials.gov14 May 2026
Can peptide injections help people recover from injuries? Here’s what you need to know
The Conversation7 May 2026
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
Bioengineering & translational medicine31 Mar 2026
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (TBRIDGE-CV Phase 1/2)
ClinicalTrials.gov23 Mar 2026
Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.
Journal of proteome research25 Feb 2026
2026 Prohibited List
Sport Integrity Australia1 Jan 2026
Utilizing Thymosin Beta-4 for Anti-Aging Regenerative Therapies
PMC1 June 2021
The regenerative peptide thymosin beta4 accelerates dermal healing in preclinical models and patients
PubMed1 Oct 2012
Thymosin beta4: a multi-functional regenerative peptide
PubMed1 Nov 2011
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
ClinicalTrials.gov1 Jan 2009
Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development
PubMed1 Mar 2004

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.